Latest Press Release
Our Story
Our path towards a new class of safe and effective therapeutics started in 2000, with the unexpected discovery by CureVac founder Ingmar Hoerr of the therapeutic potential of messenger RNA (mRNA). Although used by all cells of the body as a blueprint to build proteins based on instructions written in the genetic code of DNA, mRNA was thought too unstable to be harnassed for medical purposes. For the first time, through CureVac’s development activities this remarkable molecule started to reveal its huge potential in treating disease to evoke a broad and balanced immune response. CureVac is revolutionizing medicine to protect and improve people’s lives.
CureVac's Strengths
We are pioneers in developing mRNA medicines
Diversified and deep pipeline focused on oncology and infectious disease candidates
Proprietary RNA technology platform enabling product candidates to be active at very low doses while at the same time inducing potentially longer-lasting immune responses
Strong strategic partners including The University of Texas MD Anderson Cancer Center, one of the world’s most respected centers focused on cancer patient care, research, education and prevention